glp 1 agonist alcohol GLP-1 Anti-Obesity Rx and and Substance Use Disorders glp-1 alcohol absorption study october
Description
In comparison, less than 5% of participants combining semaglutide with lifestyle interventions gain weight, around 10% lose between 1-10%, and 87% lose more than 10%
Some data suggests that higher doses of tirzepatide may be associated with a higher risk of gastrointestinal issues compared to semaglutide
On October 8, the Congressional Budget Office (CBO) released a report on the potential federal cost if Medicare decides to cover anti-obesity medications (AOMs) for weight loss, including the much-discussed class of glucagon-like peptide 1s (GLP-1s)
Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JF, Bakris G, et al
If you stop the treatment, the disease comes back
Bedside ultrasound assessment of gastric content: an observational study
